Study summary

A myeloma bispecific antibody showed rapid activity in relapsed AL amyloidosis

Linvoseltamab phase 1/2 study · Phase 1/2 · Presented May 2026 (ASCO)

What was tested

Linvoseltamab, a BCMA-targeting bispecific antibody approved for multiple myeloma, for relapsed or refractory AL amyloidosis.

What they found

• Showed rapid blood responses in relapsed disease.
• No dose-limiting side effects were reported.
• A randomized comparison of two doses is planned, and a phase 3 trial against first-line Dara-VCd is set to start.

What it means

Experts called the data potentially practice-changing; T-cell engagers may move into first treatment.